Status:
COMPLETED
Relation Between Plasma Apelin Level and Diabetic Nephropathy in Type 2 Diabetes Patients.
Lead Sponsor:
Cairo University
Conditions:
Diabetic Nephropathies
Eligibility:
All Genders
20-60 years
Brief Summary
Diabetic nephropathy (DN) is the commonest cause of chronic kidney disease, and proteinuria isn't determent factor for the end stage renal disease in diabetics. Apelin is adipokine and have a benefici...
Detailed Description
Introduction Type 2 Diabetes Mellitus is a metabolic syndrome associated with hyperglycemia due to defect in secretion or action of insulin or both. Long term hyperglycemia leads to complications of m...
Eligibility Criteria
Inclusion
- type 2 diabetes patients of both sexes ,20-60 years of age
Exclusion
- Patients with nephropathy due to other causes than diabetes, hepatic, intrinsic renal or coronary artery disease, patients with diabetic neuropathy and retinopathy and hypertensive patient on angiotensin receptor blockers (ARBS) or angiotensin converting enzyme inhibitors (ACEI)
Key Trial Info
Start Date :
November 30 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 29 2020
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04380584
Start Date
November 30 2019
End Date
March 29 2020
Last Update
May 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo university hospitals
Cairo, Manial, Egypt, 12511